Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: Assessment by different bleeding classifications

Victor Serebruany, Sunil V. Rao, Matthew A. Silva, Jennifer L. Donovan, Abir O. Kannan, Leonid Makarov, Shinya Goto, Dan Atar

Research output: Contribution to journalArticle

Abstract

AimsTo correlate inhibition of platelet aggregation (IPA) with bleeding events assessed by TIMI, GUSTO, and BleedScore™ scales in a large cohort of patients with coronary artery disease (CAD) and ischaemic stroke (IS) treated with chronic low-dose aspirin plus clopidogrel. Data from recent trials and registries suggest a link between increased risk of bleeding and cardiovascular mortality. However, the potential association of bleeding risk and IPA is not established. It may play a critical role for the safety of more aggressive platelet inhibition or/and individual tailoring of antiplatelet strategies.Methods and resultsSecondary post hoc analyses of 5 M ADP-induced IPA and bleeding complications assessed by TIMI, GUSTO, and BleedScore™ scales in a combined data set consisting of patients with documented CAD (n = 246) and previous IS (n = 117). Demographic characteristics differ substantially depending on the underlying vascular disease; however, IPA and bleeding risks were similar between CAD and IS. All three bleeding scales adequately captured serious haemorrhagic events, where the TIMI scale was the most exclusive, whereas BleedScore™ was the most inclusive. Over half of all patients experienced superficial event(s), most commonly occurring during two to three distinct bleeding episodes. There was no correlation between IPA and duration of antiplatelet therapy. Inhibition of platelet aggregation >50 strongly correlates with minor (r2 = 0.58, P <0.001; c-statistic = 0.92), but not severe (r2 = 0.11, P = 0.038; c-statistic = 0.57), bleeding events.ConclusionChronic oral combination antiplatelet regimens are associated with a very high (56.5-60.7) prevalence of superficial bleeding episodes, which are grossly underestimated in trials and registries. The role of such frequent mild complications for the overall benefit of antiplatelet therapy is entirely unknown, as is their effect on compliance. Although IPA is well suited for defining the risk of minor complications, prediction of more severe bleeding events may be challenging.

Original languageEnglish (US)
Pages (from-to)227-235
Number of pages9
JournalEuropean Heart Journal
Volume31
Issue number2
DOIs
StatePublished - Jan 2010

Keywords

  • Bleeding events
  • Classifications
  • Platelet aggregation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: Assessment by different bleeding classifications'. Together they form a unique fingerprint.

  • Cite this